Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anne Marthe Ringerud"'
Autor:
Gro Live Fagereng, Anne Marit Morvik, Sara Reinvik Ulimoen, Anne Marthe Ringerud, Iselin Dahlen Syversen, Erik Sagdahl
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Over the preceding decade, an increasing number of drugs have been approved by the European Medicines Agency (EMA) with limited knowledge of their relative efficacy. This is due to the utilization of non-randomized, single-arm studies,
Externí odkaz:
https://doaj.org/article/3f28c14ba4a143f085a7a715f327f863
Autor:
Stuart McTaggart, Irene Langer, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Anne Marthe Ringerud, Angela Timoney, Jurij Fürst, John Yfantopoulos, Arianit Jakupi, Tatjana Ponorac, Robert Sauermann, Vanda Marković-Peković, Dzintars Gotham, D Tomek, Admir Malaj, Corinne Zara, Christian Hierländer, Peter Skiold, Vincent de Valk, Guenka Petrova, Antony P. Martin, JF (Hans) Piepenbrink, Jolanta Gulbinovič, Janet Wale, Iris Hoxha, Wouter Hamelinck, Maria Juhasz-Haverinen, Nataša Grubiša, Steven Simoens, Catherine Sermet, Ott Laius, Gisbert Selke, Robert Plisko, Celia C. Rothe, Tomasz Bochenek, Andrew F. Hill, Tanja Novakovic, Zornitza Mitkova, Ileana Mardare, Alan Haycox, Roberta Joppi, Carolin Hagen, Magdalene Wladysiuk, Amanj Kurdi, Elita Poplavska, Brian Godman, Merce Obach Cortadellas, Mark Parker
Publikováno v:
Generics and Biosimilars Initiative Journal
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to compreh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0009ea13d1e0e5433c3f43ffb8a0034b
https://ruj.uj.edu.pl/xmlui/handle/item/257394
https://ruj.uj.edu.pl/xmlui/handle/item/257394
Autor:
Stuart McTaggart, Kristina Garuoliene, Jurij Fürst, Scott M Bryson, Andrew Martin, Winne de Bruyn, Antra Fogele, Agnes Vitry, Hanne Bak Pedersen, Catherine Sermet, Gisbert Selke, Anne Marthe Ringerud, Krijn Schiffers, Eva Andersén Karlsson, Michael Wilcock, Anita Viksna, Irene Langner, Ljiljana Sović-Brkičić, Anna Coma Fusté, Marija Kalaba, Mikael Hoffmann, Peter Skiold, Sisira Jayathissa, Vanda Marković-Peković, Tomasz Bochenek, Einar Magnusson, Ott Laius, Christoph Baumgärtel, Scott Metcalfe, Corinne Zara, Brian Godman, D Tomek, Jutta Piessnegger, Rickard E. Malmström, Juraj Slabý, Harald Herholz, Jessica Fraeyman, Hye-Young Kwon, Marco D’Agata
Publikováno v:
Generics and Biosimilars Initiative Journal. 4:125-135
The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain: its principal indication. The manufacturer has threatened legal action in the UK if generic pregabalin rather than Lyrica is prescribed for this indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fb38f15e5d3afb567a542ef059014b
https://doi.org/10.5639/gabij.2015.0403.028
https://doi.org/10.5639/gabij.2015.0403.028
Autor:
Agnes Vitry, Brian Godman, Corrine Zara, Hanna Koskinen, Harald Herholz, Marion Bennie, Christoph Baumgärtel, Catherine Sermet, Anne Marthe Ringerud
Resource pressures will continue to grow. Consequently, health authorities and health insurance agencies need to take full advantage of the availability of generics in order to continue funding comprehensive health care particularly in Europe. Generi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f28aea7afa4b9a29e5f7fa0451a375
https://hdl.handle.net/1959.8/125377
https://hdl.handle.net/1959.8/125377